A methodological approach to the marketing process in the biotechnology-based companies

Product Description
This digital document is a journal article from Industrial Marketing Management, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
The article addresses the commercialization activities of biotechnology-based companies in a European context and discusses whether these companies are able to gain adequate market perceptions and set adequate marketing processes, taking into account three analytical steps: strategic marketing definition, marketing implementation, and evolution of strategy and implementation. A methodological approach was developed, considering the specific nature of the technology and the companies. The case of Portuguese companies was used to test this methodology. The findings support the hypothesis that marketing issues constitute a problem for these companies, since most of them had serious difficulties in going through the marketing process. Marketing deficiencies were largely connected to the access to human resources with relevant management and marketing capabilities and were particularly felt by companies introducing discontinuous innovations. The research confirms that this methodology is useful in the assessment of the marketing management process in biotechnology-based companies.

A methodological approach to the marketing process in the biotechnology-based companies

2004 Executive’s Guide to the World’s Leading Pharmaceutical and Biotechnology Companies

Product Description
The Wood Mackenzie 2004 Executive’s Guide is an indispensable reference source for pharmaceutical and biotechnology executives. Now in its 17th edition, the Guide provides at-a-glance statistics and analysis of the WoodMac 50, Wood Mackenzie’s top 50 pharmaceutical and biotechnology companies.

For 2004, the Guide contains an expanded series of company summaries, a ranking table for the WoodMac 50 and an in-depth analysis of opportunities and critical issues for the pharmaceutical and biotechnology industries.

The 2004 edition includes:

-Five for ‘05: Our top five issues and trends that life sciences companies will face in the coming year
-Concise executive summaries for each of the WoodMac 50
-Wood Mackenzie’s Freshness Index, which measures the health of pipelines based on portfolio maturity
-Company rankings for the WoodMac 50
-In-depth analysis of key therapeutic areas, companies and products in 2003

2004 Executive’s Guide to the World’s Leading Pharmaceutical and Biotechnology Companies

In-Depth Look – Biotech Companies Struggle With Shortages – Bloomberg

Interview and discussion with Dr. Robert Glassman of the Weill Cornell Medical College. He talks about the potential growth in the drug industry. (Bloomberg News)

In-depth Analysis of the Leading Healthcare Biotechnology Companies

Top 10 Biotech Companies Market Report ( http://www.bharatbook.com/Market-Research-Reports/Top-10-Biotech-Companies-Market-Outlook-2008-2023.html ) examines the product portfolios of the leading companies critically, with in-depth analysis, especially market forecasting and qualitative analysis of market drivers and restraints. The result is a comprehensive market-based report with detailed analysis and informed opinion.
 
 The leading healthcare biotechnology companies will continue to make strong inroads into the overall global pharma industry and market in the years ahead, with rising stars competing too. Do you know how sales of leading biotech companies will develop over the coming years? Do you know the prospects for other biotech organisations? Concludes that there will be increasing reliance on biological drugs as time goes by, especially for recalcitrant diseases with significant unmet needs. The commercial and technological opportunities for greater personalisation of medicine through biotechnology are very exciting. Certainly, the commercial opportunities for dynamic healthcare biotech companies are significant. The development of more-personalised medicine promising greater efficacy and safety – particularly in cancer treatment – is a major commercial hope. By purchasing this report, you will be better prepared to appreciate those major developments in the global pharmaceutical market.
 
 The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics – amongst others – the biotechnology market has experienced great expansion since its emergence during the 1970’s. The leading healthcare biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other healthcare biotech companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market. Our new report – Top-10 Biotech Companies – Market Outlook, 2008-2023 – will help you to understand those developments and their significance. That report provides valuable commercial information on this exciting industry that no healthcare company should ignore.
 
 Over the period 2008 to 2023, the healthcare biotechnological market continuing its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development. There remain significant unmet needs in this market, with great opportunities for companies that can develop safer and better-targeted treatments.
 
 For more information please visit : http://www.bharatbook.com/Market-Research/Biotechnology.html
 
 Or
 
 Contact us at:
 
 Bharat Book Bureau
 Tel: +91 22 27578668
 Fax: +91 22 27579131
 Email: info@bharatbook.com
 Website: www.bharatbook.com

The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles—Aarkstore Enterprise

Aarkstore announce a new report  “The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles” through its vast collection of market research report.

The Fastest Growing Biotechnology Companies

In recent years, the biopharmaceutical industry has emerged as one of the most important sectors in the Healthcare field. Advances in life sciences have resulted in the drug discovery process becoming more science-intensive, with an increasing emphasis on cross-company collaborations and the exchange of information. However, growing commercial pressures and rising R&D costs have prompted many biotech companies to seek financial support from global Big Pharma corporations through licensing and collaborative R&D deals. Progressive enhancements in integration have subsequently led to traditional pharma companies becoming increasingly dependant upon the technology platforms and approaches adopted by biotech companies.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles is a new report examines the structure and organization of the biopharmaceutical industry with a detailed analysis of the fastest growing biotechnology companies. This report provides a comparative analysis of growth strategies and reviews the methods used to improve operational efficiency in light of cost pressures, generic competition, complex pricing, regulations, and globalization. This report also explores the levels of interaction and integration between biopharma companies and the wider pharma industry.
Use key indicators to assess the performances of the fastest growing biotech companies, benchmark their most successful strategies and understand major industrial issues with this new report.

Top five reasons to order your copy today

• Identify the fastest growing biotech companies over the 2002-06 period, and use detailed company analysis to measure the performances and outlooks of major players including Theravance, ISTA, Palatin, Pharmion, Amylin, Trimeris, ViroPharma, NPS, SIGA and Idenix.
• Discover which therapeutic areas have been targeted by the fastest growing biotech companies and determine which strategies they have used to exploit proprietary technologies and intellectual property.
• Review the progress of biotech development programs and understand the regulatory status of new products in development, patents held and the current status of marketed products.
• Benchmark the strategies of the fastest growing biotech companies with this report’s assessment of the effectiveness and wider implications of a host of leading strategic implementations.
• Understand how biopharma drug discovery programs are being improved to develop more efficient methods in the screening of new chemical entities (NCEs).

Key issues examined in this report…

• Biotech losses. Only eleven of the world’s top twenty biotechnology companies currently attain a positive net income. This trend is a key industry-wide issue, with companies now attempting to stabilize financial performance.
• Developmental uncertainty. Biotherapeutic developments continue to face a high level of uncertainty. A wide array of factors can contribute to the delay or late-stage failure of promising products.
• External investment. Time-consuming, risky and expensive biopharma product developments require high levels of investment and investor patience, as market-generated revenues are often late in materializing. Investors often pursue milestone payments, joint ventures, out-licensing deals, or M&A as alternative exit strategies.
• Partnership trends. The majority of dedicated biotech companies have attempted to establish strategic alliances, joint ventures and even mergers between themselves and major pharma companies.

Some key findings from this report…

• Theravance, Inc. is the fastest growing biotechnology company in the world, with a growth rate of 12,456% over the 2002-06 period. However, Theravance also has one of the highest levels of net losses within the industry, highlighting the need to sustain more stable, predictable and stronger financial performance.
• ISTA Pharmaceuticals, Inc is the world’s second fastest growing biotechnology company, with a growth rate of 11,773% between 2002-06. Palatin Technologies, Inc. is in third position with a growth rate of 6,928% during the same period.
• Amylin Pharmaceuticals, Inc. recorded the greatest sales gains over 2002-2006, with an increase of $497.4mn during this period.
• The top 10 fastest growing biotechnology companies had a combined R&D expenditure of $734mn in 2006. This constitutes an increase of $324.7mn since 2002, and a five year growth rate of 179%.
• Flexible or adaptive clinical trial designs and proprietary Internet applications are helping to bring products to market faster by improving the efficiency of clincial trials. A prominent example of this is MetaTrial’s Electronic Data Capture (EDC) software.

Your questions answered…

• Who are the fastest growing biotechnology companies in the world?
• What is their level of R&D expenditure and how does this compare to their revenues?
• What proportion of biotech company revenues are accounted for by marketed products?
• What license agreements, joint ventures and partnerships have been established by the fastest growing biotech companies?
• How profitable is the biopharmaceutical industry?
• What key strategic tactics are being adopted by the fastest growing biotech companies in R&D, product commercialization, cost containment, manufacturing and screening/development of NCEs?
• What are the strengths, weaknesses, opportunities and threats to each of the companies profiled within this report?
• What is the product pipeline status of major biotech companies?

For more information, please visit :
http://www.aarkstore.com/reports/The-Fastest-Growing-Biotechnology-Companies-Growth-strategies-comparative-analyses-and-company-profiles-14422.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

« Previous Page — Next Page »